CRISPR Reverses Huntington’s Disease in Mice
The potential of genome-editing techniques, such as CRISPR/Cas9 to relieve disease burden has been encouraged by a number of researchers.
Now, a group of investigators led by scientists at Emory University is hoping to expand neurodegenerative research and move toward human trials after the release of their new findings. In a test with mice, they have proved that CRISPR can reverse Huntington’s disease.
Findings from the new study were published today in the Journal of Clinical Investigation through an article entitled, “CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease.”
They showed that the CRISPR/Cas9 system could snip part of a gene that produces toxic protein aggregates in the brains of 9-month-old mice used as a model for Huntington’s disease. Moreover, the scientists noted that when they looked at the brain region where the vector was applied, some weeks later, the aggregated proteins had almost disappeared. The motor abilities of the mice had improved, although not to the level of control mice.
Huntington’s disease is caused by a gene encoding a toxic protein (mutant huntingtin or mHTT) that causes brain cells to die. Symptoms commonly appear in mid-life and include uncontrolled movements, balance problems, mood swings, and cognitive decline. The mice used in the current study have a human mHTT gene replacing one of the mouse huntingtin genes. In these mice, motor problems and aggregated mHTT can be observed around the age of 9 months.
“We report that permanent suppression of endogenous mHTT expression in the striatum of mHTT-expressing mice (HD140Q-knockin mice) using CRISPR/Cas9-mediated inactivation effectively depleted HTT aggregates and attenuated early neuropathology,” the authors said. “The reduction of mHTT expression in striatal neuronal cells in adult HD140Q-knockin mice did not affect viability, but alleviated motor deficits. Our studies suggest that non–allele-specific CRISPR/Cas9-mediated gene editing could be used to efficiently and permanently eliminate polyglutamine expansion-mediated neuronal toxicity in the adult brain.”
When forward planning the gene editing, the scientists selected guide sequences that targeted both the normal copy and the disease-driving driving copy of the huntingtin gene. This “non-allele specific” approach would not need to be customised to the patient’s genome, unlike other gene-editing proposals for Huntington’s disease. The researchers previously showed that mice older than four months do not need the huntingtin gene to stay healthy, suggesting that treatment strategies that aim to shut off both copies of the gene in adult humans could be safe.
The challenge in the current research came from trying to target the gene-editing system to the appropriate area of the brain. To achieve this, the research team joined a widely used gene-therapy vehicle based on AAV (adeno-associated virus). The scientists injected viral vectors carrying CRISPR/Cas9 into the striatum region of the brains of Huntington’s disease model mice at the age of nine months. The striatum is a region of the brain that controls body movement and motor function.
This led to a dramatic decrease in aggregated mHTT in the striatum three weeks later. The study revealed the capacity of brain cells to heal themselves if the genetic source of the toxic proteins is removed. In comparison with control Huntington’s mice, CRISPR/Cas9-injected mice showed significant improvements on tests of motor control, balance, and grip strength, although they did not recover to the point where they performed as well as control mice.
Attempting to address genetic safety concerns, the researchers showed that in brain cells, frameshift mutations triggered by CRISPR/Cas9 occurred predominantly within the huntingtin gene and not in other potential off-target genes. However, the authors noted that the long-term effects and safety of injecting AAV in the brain to express CRISPR/Cas9 needs to be rigorously tested before applying this approach to patients.